Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives

Monoclonal antibodies (mAbs) targeting specific proteins are currently the most popular form of immunotherapy used in the treatment of cancer and other non-malignant diseases. Since the first approval of anti-CD20 mAb rituximab in 1997 for the treatment of B-cell malignancies, the market is continuo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bobrowicz, Malgorzata, Zagozdzon, Radoslaw, Domagala, Joanna, Vasconcelos-Berg, Roberta, Guenova, Emmanuella, Winiarska, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826541/
https://www.ncbi.nlm.nih.gov/pubmed/31554169
http://dx.doi.org/10.3390/cancers11101420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826541/
https://www.ncbi.nlm.nih.gov/pubmed/31554169
http://dx.doi.org/10.3390/cancers11101420

Ejemplares similares